| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Beta-glucans are polysaccharides found in the cell walls of certain fungi, bacteria, and plants. • Enhanced anti-tumor activity: Beta-glucans have been shown to stimulate the immune system, increasing the production of cytokines and activating natural killer cells, which can help to destroy cancer cells. • Improved survival rates: • Increased expression of tumor suppressor genes: • Inhibition of cancer cell proliferation: • Enhanced chemotherapy efficacy: • Reduced cancer recurrence: beta-glucans — Beta-glucans are structurally diverse glucose polymers, most commonly β-(1→3)/(1→6)-linked fungal or yeast polysaccharides and β-(1→3)/(1→4)-linked cereal polysaccharides, that function primarily as innate immune response modifiers rather than conventional directly cytotoxic small molecules. They are best classified as immunomodulatory polysaccharides / biological response modifiers, with common abbreviations including β-glucan, BG, and for specific products lentinan or LNT. Their biological activity is highly source-, branching-, solubility-, and particle-size-dependent, which is a major reason why “beta-glucans” should be treated as a family rather than a single interchangeable agent. In oncology, the strongest evidence base is for adjunctive use of selected fungal β-glucans, especially lentinan-based regimens in East Asian practice, rather than for broad standalone anticancer efficacy. Primary mechanisms (ranked):
Bioavailability / PK relevance: Oral beta-glucans are generally poorly digested and have limited measurable systemic absorption; clinical activity after oral dosing is thought to depend mainly on gut-associated immune signaling and downstream myeloid activation. Injectable purified fungal preparations such as lentinan bypass part of this delivery constraint and are more relevant to oncology translation. In-vitro vs systemic exposure relevance: Many direct tumor-cell effects reported in vitro use purified products and exposure conditions that are not easily mapped to achievable systemic concentrations after oral supplementation. For most oral products, the clinically relevant mechanism is not high free plasma exposure but immune-cell and mucosal engagement. Clinical evidence status: Adjunctive human evidence exists, strongest for selected purified fungal β-glucans such as lentinan combined with chemotherapy in gastric cancer, but the class as a whole remains heterogeneous and is not established as a standalone anticancer therapy. Overall evidence level: preclinical to small/moderate human adjunctive, with limited high-quality modern global RCT standardization. reference summaries describe about 2–10 mg IV lentinan weekly as the general adjunctive range used in Japan with chemotherapy.In general, bigger size and more complex β-glucans such as those derived from Ganoderma lucidum have higher immunomodulating potency. Lentinan(LNT) are macromolecules with a β-1,3-D-glucan and its unique molecular structure is closely related to its pharmacological activity, and the glucan of the β-glycosidic bond is the key structure for its antitumor function. Beta-glucans are not one thing. Cancer relevance depends more on source, linkage pattern, branching, solubility, and molecular weight/conformation than on the name alone. The table below is a practical comparison of the main beta-glucan families, with effectiveness interpreted as the strength of anticancer evidence, not a direct potency score.
Mechanistic matrix
P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: CGL-CS |
| Type: |
| Mitogen-activated protein kinases (MAPKs) are a group of proteins involved in transmitting signals from the cell surface to the nucleus, playing a crucial role in various cellular processes, including growth, differentiation, and apoptosis (programmed cell death). MAPK Pathways: The MAPK family includes several pathways, the most notable being: 1.ERK (Extracellular signal-Regulated Kinase): Often associated with cell proliferation and survival. 2.JNK (c-Jun N-terminal Kinase): Typically involved in stress responses and apoptosis. 3.p38 MAPK: Associated with inflammatory responses and apoptosis. Inhibitors: Targeting the MAPK pathway has become a strategy in cancer therapy. For example, BRAF inhibitors (like vemurafenib) are used in treating melanoma with BRAF mutations. Altered Expression Levels: Overexpression: Many cancers exhibit overexpression of MAPK pathway components, such as RAS, BRAF, and MEK. This overexpression can lead to increased signaling activity, promoting cell proliferation and survival. Downregulation: In some cases, negative regulators of the MAPK pathway (e.g., MAPK phosphatases) may be downregulated, leading to enhanced MAPK signaling. The expression levels of MAPK pathway components can serve as biomarkers for cancer diagnosis, prognosis, and treatment response. For example, high levels of phosphorylated ERK (p-ERK) may indicate active MAPK signaling and poor prognosis in certain cancers. Numerous reports indicate that the MAPK pathway plays a major role in tumor progression and invasion, while inhibition of MAPK signaling reduces invasion. |
| 874- | B-Gluc, | Potential promising anticancer applications of β-glucans: a review |
| - | Review, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:245 Target#:181 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid